<DOC>
	<DOCNO>NCT02258685</DOCNO>
	<brief_summary>This study plan learn immune response intestinal ( gut ) tissue people human immunodeficiency virus ( HIV ) infection . This study determine whether change composition gut bacteria HIV infect individual relate high prevalence chronic gut inflammation metabolic disease . The investigator also investigate immune-modulatory property specific bacteria correlate disease characterize functional gene select genome stimulate immune cell isolate blood gut tissue bacterial isolates . This work establish whether gain/loss bacterial drivers/suppressors information gut contribute metabolic disease HIV-infected individual .</brief_summary>
	<brief_title>Factors Mediating Gut Microbiota Dysbiosis Metabolic Disease HIV Patients .</brief_title>
	<detailed_description>This prospective cohort cross-sectional case-control study . Study participation last 2 month 93 participant enrol . Participants evaluate lipodystrophy , ask complete food &amp; gastrointestinal symptom questionnaire provide stool sample . A subset participant ask flexible sigmoidoscopy ( mucosal biopsy ) . Cohort A consist 93 participant : Cohort A1 : ART ( Antiretroviral therapy ) -treated HIV-infected individual lipodystrophy ( n=35 ) Cohort A2 : ART-treated HIV-infected individual without lipodystrophy ( n=18 ) Cohort A3 : HIV-1 infected individual naïve ART ( n=20 ) Cohort A4 : HIV-1 seronegative individual high risk infection ( n=20 ) Cohort B select subset subject Cohort A : Cohort B1 : ART-treated HIV-infected individual HIV-associated dysbiosis ( n=10 ) Cohort B2 : ART-treated HIV-infected individual without HIV-associated dysbiosis ( n=10 )</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Dysbiosis</mesh_term>
	<criteria>Men woman ; 18 year 65 year ( All Cohorts ) Subjects chronic HIV1 Infection define positive ELISA confirm positive Western Blot plasma HIV1 RNA level &gt; 1,000 copies/mL time past . ( Cohorts A1 , A2 &amp; A3 ) HIV1 seronegative ( Cohort A4 ) Either without lipodystrophy ( assessed Visit 1 ) Body mass index ( BMI ) 2129 mg/kg2 weight stable least 3 month ( All Cohorts ) Antiretroviral therapy ( ART ) naïve ( Cohort A3 ) : &lt; 10 day ART treatment time prior Visit 1 previously ART treatment previous 6 month prior Visit 1 Longterm ART ( Cohort A1 &amp; A2 ) : Must antiretroviral treatment plasma HIV1 RNA &lt; 25 copies/mL 36 month prior Visit 1.Liver function test great 2x normal , normal kidney thyroid function . Fasting glucose must &lt; 110 mg/dl Liver function test great 2x normal , normal kidney thyroid function . Fasting glucose must &lt; 110 mg/dl ARTtreated individual whose microbiota resemble untreated HIV infection ARTtreated individual whose microbiota resemble HIVnegative control cohort ( equal number without lipodystrophy ) . ( Cohort B ; subset Cohort A ) Gastrointestinal disease inflammatory bowel disease , Clostridium difficile colitis celiac sprue . history bowel resection , bleed disorder , history hyperglycemia , treat highdose glucocorticoid therapy alphainterferon past year Current use anticoagulant therapy Daily use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) inability withhold drug 7 day rectosigmoid biopsy procedure . Used antibiotic within prior three month Pregnancy Current use proton pump inhibitor H2blockers Active opportunistic chronic infection , hepatitis B C active malignancy Patient inability participate study , inability undergo venipuncture , completion questionnaire mucosal biopsy ( select ) procedure form part inclusion/exclusion criterion part outcome measure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gut microbiota composition</keyword>
</DOC>